摘要
近年来非霍奇金淋巴瘤(NHL)的发病率逐渐上升,弥漫大B细胞淋巴瘤(DLBCL)是其最常见类型,尽管利妥昔单抗联合化疗获得了明显疗效,但仍有30%~40%的患者会发展为复发难治DLBCL。这类患者治疗方案有限且预后差,近年来有关复发难治DLBCL的治疗已成为国内外研究热点。文章就新型靶向药物及免疫治疗进行综述。
In recent years,the incidence of non-Hodgkin lymphoma(NHL)has gradually increased.Diffuse large B-cell lymphoma(DLBCL)is the most common type of NHL.Although rituximab combined with chemotherapy has achieved significant efficacy,there are still 30%-40%of patients that will develop relapsed/refractory DLBCL.These patients have limited treatment options and poor prognosis.In recent years,the treatment of relapsed/refractory DLBCL has become a research hotspot at home and abroad.This article reviews the progress of new targeted drugs and immunotherapy.
作者
曾静
杨洋
魏华英
陈雪
仵永枫
画伟
郭彩萍
张玉林
Zeng Jing;Yang Yang;Wei Huaying;Chen Xue;Wu Yongfeng;Hua Wei;Guo Caiping;Zhang Yulin(Department of Infectious Diseases,Beijing Youan Hospital,Capital Medical University,Beijing 100069,China)
出处
《白血病．淋巴瘤》
CAS
2020年第12期757-761,共5页
Journal of Leukemia & Lymphoma
基金
国家自然科学基金(81873761)
"十三五"国家科技重大专项(2018ZX10302104)。
关键词
淋巴瘤
大B-细胞
弥漫性
复发
难治
分子靶向治疗
免疫治疗
Lymphoma,large B-cell,diffuse
Recurrence
Refractory
Molecular targeted therapy
Immunotherapy
